- Gilead collaboration results in cash infusion of $150M; first milestone payment of $7.5M triggered - CTLA-4 & PD-1 trials are accruing for planned BLA filing as early as 2020 - Next-Gen CTLA-4 advancing - expect first patient to be dosed this month - First year revenues of GSK's SHINGRIX

- FDA has accepted IND filing for AGEN1423 LEXINGTON, Mass., March 13, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that the FDA has

LEXINGTON, Mass., March 8, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its fourth quarter and full year 2018 financial results before the market

-- Agenus Conference Call and Live Webcast Scheduled for 11:00a.m. ET today -- LEXINGTON, Mass., Feb. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1,

LEXINGTON, Mass., Feb. 15, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today that its Biotech Electronic Security Token (BEST), the first

- The Biotech Electronic Security Token (BEST) is designed to be an innovative and transformative way to finance drug development through increasing liquidity, minimizing dilution, and improving capital allocation - BEST democratizes financing through targeted investments for specific therapeutic

LEXINGTON, Mass., Jan. 24, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its immuno-oncology (I-O) partnership deal with Gilead Sciences,

- Bill & Melinda Gates Foundation invests ~$1M to develop novel technology for QS-21 - Grant to develop an alternative, novel plant cell-culture based method for QS-21 production LEXINGTON, Mass., Jan. 3, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a

-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET -- FOSTER CITY, Calif. and LEXINGTON, Mass., Dec. 20, 2018 / PRNewswire / -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O)

LEXINGTON, Mass., Nov. 13, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the election of Dr. Allison Jeynes-Ellis to Agenus' Board of Directors and the